美克洛嗪使用与头晕患者后续跌倒的关系
这项队列研究分析了2006至2015年美国商业和Medicare Advantage保险索赔中805 454例新诊断头晕的成人(≥18岁)。8%在诊断后30天内获得美克洛嗪处方,校正社会人口学和临床因素后,美克洛嗪处方与18-64岁(HR 2.94;95%CI 2.81-3.08)和≥65岁(HR 2.54;95%CI 2.42-2.66)患者后续跌倒相关。作者认为美克洛嗪使用与指南一致诊疗不符,未来可能有必要制定指南以推动停用常规前庭抑制剂。
要点
- 805 454例头晕成人中8%在诊断后30天内获得美克洛嗪处方。
- 美克洛嗪处方者中9%(5792例)发生需医疗评估的跌倒。
- 校正后美克洛嗪与18-64岁(HR 2.94)和≥65岁(HR 2.54)跌倒风险增加相关。
核心结论
- 美克洛嗪可能提供即刻眩晕缓解,但其使用与常见前庭诊断的指南一致诊疗不符。
- 在≥65岁和18-64岁头晕患者中,获得美克洛嗪处方与伤害性跌倒风险增加相关,这些患者本已易跌倒。
- 未来前瞻性和机制研究可能进一步阐明前庭抑制剂与跌倒风险的关系,未来可能有必要制定指南让临床医生和患者参与停用常规前庭抑制剂。
研究设计与样本
- 这项队列研究评估2006至2015年美国商业和Medicare Advantage保险索赔中805 454例新诊断头晕的成人(≥18岁)。
- 数据分析时间为2024年7月至2025年2月。
- 暴露为在新头晕诊断后30天内获得美克洛嗪处方。
主要发现
- 805 454例头晕个体中502 055例为女性(62%),中位年龄52岁(范围18-87岁)。
- 8%获得美克洛嗪处方。
- 美克洛嗪处方者中5792例(总体9%;18-64岁10%[2189/21 700],≥65岁9%[3603/40 138])发生伤害性跌倒。
- 校正社会人口学和临床因素后,填写的美克洛嗪处方与18-64岁后续跌倒相关(HR 2.94;95%CI 2.81-3.08)。
- 校正社会人口学和临床因素后,填写的美克洛嗪处方与≥65岁后续跌倒相关(HR 2.54;95%CI 2.42-2.66)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Among adults who present with dizziness, there is a critical need to identify and deimplement low-value and guideline-discordant care to mitigate the risk of falls over time. Meclizine, an antihistamine with anticholinergic properties, is the most used antiemetic vestibular suppressant in the US. OBJECTIVE: To determine the factors associated with meclizine use and subsequent falls among patients aged 18 to 64 years and those aged 65 years or older with dizziness. DESIGN, SETTING, AND POPULATION: This cohort study assessed US commercial and Medicare Advantage claims among 805 454 adults (aged ≥18 years) with new diagnoses of dizziness between 2006 and 2015. Data were analyzed from July 2024 to February 2025. EXPOSURE: Prescription of meclizine within 30 days of a new dizziness diagnosis. MAIN OUTCOMES AND MEASURES: The main outcome measure was falls resulting in medical evaluation. Fall outcomes were attributed to meclizine use if they occurred within 60 days of a meclizine prescription. Associations of falls and meclizine with presentation setting, diagnoses, and sociodemographic characteristics were estimated with multivariable analyses. RESULTS: Of 805 454 individuals with dizziness (502 055 women [62%]; median age, 52 years [range, 18-87 years]), 8% received a meclizine prescription. Among those prescribed meclizine, 5792 (9% overall; 10% [2189/21 700] aged 18-64 years and 9% [3603/40 138] aged ≥65 years) experienced an injurious fall. When adjusting for sociodemographics and clinical factors, a filled meclizine prescription was associated with subsequent falls in those aged 18 to 64 years (hazard ratio, 2.94; 95% CI, 2.81-3.08) and those aged 65 years or older (hazard ratio, 2.54; 95% CI, 2.42-2.66). CONCLUSIONS AND RELEVANCE: This study found that although meclizine may offer immediate vertigo relief, use is incongruent with guideline-concordant care for common vestibular diagnoses. Receipt of a meclizine prescription was associated with an increased risk of injurious falls among both patients aged 65 years or older and those aged 18 to 64 years with dizziness, who are already fall prone. Future prospective and mechanistic studies may further elucidate the relationship between vestibular suppressants and fall risk, and future guidelines that engage clinicians and patients to deimplement routine vestibular suppressant use for dizziness may be warranted.
引用
- Adams ME, Karaca-Mandic P, Marmor S, et al. Meclizine Use and Subsequent Falls Among Patients With Dizziness. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40705353. doi:10.1001/jamaoto.2025.2052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。